<!DOCTYPE html>
<html lang="en" data-arca>
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Multiple Myeloma BRA â€” ArcaScience | CAR-T, Bispecifics &amp; IMiDs</title>
  <meta name="description" content="AI-driven benefit-risk analysis for Multiple Myeloma including CAR-T cell therapy, bispecific antibodies, and IMiD safety profiling. ArcaScience covers CRS monitoring, ICANS grading, secondary malignancy surveillance, and cardiac toxicity across myeloma treatment lines.">

  <link rel="preload" href="/fonts/Inter-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="preload" href="/fonts/Literata-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="stylesheet" href="/dist/arcascience-global.min.css">

  <script>
    (function(){
      if(window.matchMedia&&window.matchMedia('(prefers-reduced-motion: reduce)').matches){
        document.documentElement.classList.add('reduced-motion');
      }
    })();
  </script>
</head>
<body>

  <div data-scroll-progress></div>

  <!-- NAVIGATION -->
  <nav class="arca-nav" data-nav="sticky" role="navigation" aria-label="Main navigation">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px; display: flex; align-items: center; justify-content: space-between; height: 100%;">
      <a href="/" aria-label="ArcaScience home">
        <img src="/images/arcascience-logo.svg" alt="ArcaScience" height="32">
      </a>
      <div style="display: flex; align-items: center; gap: 32px;">
        <a href="/" class="arca-nav-link">Home</a>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/platform-overview" class="arca-nav-link">Platform <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 240px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/platform-overview" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Platform Overview</a>
            <a href="/platform-how-it-works" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">How It Works</a>
            <a href="/platform-data-intelligence" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Data Intelligence</a>
            <a href="/platform-ai-models" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">AI Models</a>
            <a href="/platform-outputs" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Regulatory Outputs</a>
            <a href="/platform-integrations" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Integrations</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <a href="/security-compliance" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Security &amp; Compliance</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/solution-therapeutic-area" class="arca-nav-link is-active">Solutions <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 240px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <p style="padding: 6px 16px 2px; font-size: 0.7rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; color: var(--grey-400); margin: 0;">By Approach</p>
            <a href="/solution-therapeutic-area" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">By Therapeutic Area</a>
            <a href="/solution-lifecycle-phase" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">By Lifecycle Phase</a>
            <a href="/solution-role" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">By Role</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <p style="padding: 6px 16px 2px; font-size: 0.7rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; color: var(--grey-400); margin: 0;">By Stage</p>
            <a href="/solution-early-development" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Early Development</a>
            <a href="/solution-late-development" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Late Development</a>
            <a href="/solution-post-marketing" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Post-Marketing</a>
            <a href="/solution-market-access" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Market Access</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <p style="padding: 6px 16px 4px; font-size: 0.6875rem; font-weight: 600; letter-spacing: 0.08em; text-transform: uppercase; color: var(--grey-400); margin: 0;">Therapeutic Areas</p>
            <a href="/ta-oncology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Oncology</a>
            <a href="/disease-breast-cancer" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Breast Cancer</a>
            <a href="/disease-melanoma" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Melanoma</a>
            <a href="/disease-nsclc" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">NSCLC</a>
            <a href="/disease-aml" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">AML</a>
            <a href="/ta-neurology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Neurology</a>
            <a href="/disease-alzheimers" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Alzheimer's</a>
            <a href="/disease-parkinsons" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Parkinson's</a>
            <a href="/disease-multiple-sclerosis" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Multiple Sclerosis</a>
            <a href="/disease-sma" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">SMA</a>
            <a href="/ta-immunology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Immunology</a>
            <a href="/disease-rheumatoid-arthritis" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Rheumatoid Arthritis</a>
            <a href="/disease-psoriasis" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Psoriasis</a>
            <a href="/disease-lupus" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Lupus</a>
            <a href="/ta-cardiology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Cardiology</a>
            <a href="/disease-afib" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">AFib</a>
            <a href="/disease-heart-failure" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Heart Failure</a>
            <a href="/ta-respiratory" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Respiratory</a>
            <a href="/disease-asthma" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Asthma</a>
            <a href="/disease-cystic-fibrosis" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Cystic Fibrosis</a>
            <a href="/ta-rare-diseases" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Rare Diseases</a>
            <a href="/disease-sma" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">SMA</a>
            <a href="/disease-cystic-fibrosis" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Cystic Fibrosis</a>
            <a href="/ta-dermatology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Dermatology</a>
            <a href="/disease-atopic-dermatitis" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Atopic Dermatitis</a>
            <a href="/disease-psoriatic-arthritis" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Psoriatic Arthritis</a>
            <a href="/ta-hematology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Hematology</a>
            <a href="/disease-multiple-myeloma" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Multiple Myeloma</a>
            <a href="/disease-cll" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">CLL</a>
            <a href="/disease-sickle-cell" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Sickle Cell Disease</a>
            <a href="/ta-gastroenterology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Gastroenterology</a>
            <a href="/disease-crohns-disease" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Crohn's Disease</a>
            <a href="/disease-ulcerative-colitis" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Ulcerative Colitis</a>
            <a href="/ta-endocrinology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Endocrinology</a>
            <a href="/disease-type-2-diabetes" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Type 2 Diabetes</a>
            <a href="/disease-obesity" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Obesity</a>
            <a href="/ta-infectious-disease" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Infectious Disease</a>
            <a href="/disease-hiv" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">HIV</a>
            <a href="/disease-hepatitis-b" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Hepatitis B</a>
            <a href="/ta-pediatrics" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Pediatrics</a>
            <a href="/disease-pediatric-epilepsy" style="display: block; padding: 4px 16px 4px 28px; font-size: 0.75rem; color: var(--grey-500); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Pediatric Epilepsy</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/evidence-case-studies-hub" class="arca-nav-link">Evidence <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 220px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/evidence-case-studies-hub" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Case Studies</a>
            <a href="/evidence-publications" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Publications</a>
            <a href="/evidence-metrics" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Platform Metrics</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/about" class="arca-nav-link">Company <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 200px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/about" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">About ArcaScience</a>
            <a href="/leadership" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Leadership</a>
            <a href="/careers" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Careers</a>
            <a href="/science-methodology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Science &amp; Methodology</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/resources" class="arca-nav-link">Resources <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; right: -12px; min-width: 220px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/resources" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Resource Hub</a>
            <a href="/resources-whitepapers" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Whitepapers</a>
            <a href="/resources-webinars" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Webinars &amp; Events</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <a href="/resources-faq" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">FAQ</a>
            <a href="/resources-glossary" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Glossary</a>
          </div>
        </div>
      </div>
      <a href="/contact" class="arca-btn-primary" style="height: 40px; padding: 8px 24px; font-size: 0.875rem;">Talk to a Scientist</a>
    </div>
  </nav>

  <div style="height: var(--nav-height);"></div>

  <main role="main">

    <!-- HERO -->
    <section class="arca-bg-blue-900" style="position: relative; overflow: hidden; padding: var(--space-8) 0 var(--space-9);" data-animate>
      <div style="position: absolute; top: -100px; right: -100px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(16, 163, 127, 0.10) 0%, transparent 70%); border-radius: 50%; filter: blur(60px); pointer-events: none; animation: as-float 8s ease-in-out infinite; z-index: 0;"></div>
      <div style="position: absolute; bottom: -80px; left: -80px; width: 400px; height: 400px; background: radial-gradient(circle, rgba(217, 161, 12, 0.06) 0%, transparent 70%); border-radius: 50%; filter: blur(60px); pointer-events: none; animation: as-float 10s ease-in-out infinite reverse; z-index: 0;"></div>

      <svg width="420" height="320" viewBox="0 0 420 320" fill="none" aria-hidden="true" style="position: absolute; right: -20px; top: 50%; transform: translateY(-50%); opacity: 0.12; pointer-events: none; z-index: 0;">
        <circle cx="210" cy="160" r="16" stroke="rgba(16,163,127,0.5)" stroke-width="1.5" fill="none"/>
        <circle cx="210" cy="160" r="6" fill="rgba(16,163,127,0.3)"/>
        <circle cx="290" cy="100" r="10" stroke="rgba(217,161,12,0.4)" stroke-width="1" fill="none"/>
        <circle cx="130" cy="100" r="10" stroke="rgba(16,163,127,0.4)" stroke-width="1" fill="none"/>
        <circle cx="290" cy="220" r="10" stroke="rgba(16,163,127,0.4)" stroke-width="1" fill="none"/>
        <circle cx="130" cy="220" r="10" stroke="rgba(217,161,12,0.4)" stroke-width="1" fill="none"/>
        <line x1="210" y1="160" x2="290" y2="100" stroke="rgba(217,161,12,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="130" y2="100" stroke="rgba(16,163,127,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="290" y2="220" stroke="rgba(16,163,127,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="130" y2="220" stroke="rgba(217,161,12,0.3)" stroke-width="1.5"/>
      </svg>

      <div style="position: relative; z-index: 1; max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <nav aria-label="Breadcrumb" style="margin-bottom: var(--space-5);">
          <ol style="list-style: none; padding: 0; margin: 0; display: flex; align-items: center; gap: 8px; font-size: 0.75rem;">
            <li><a href="/" style="color: rgba(255,255,255,0.65); text-decoration: none;">Home</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none;">Therapeutic Areas</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/ta-hematology" style="color: rgba(255,255,255,0.65); text-decoration: none;">Hematology</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li style="color: var(--white);">Multiple Myeloma</li>
          </ol>
        </nav>

        <div style="max-width: 820px;">
          <p data-animate="fade" class="arca-label arca-text-blue-400" style="margin-bottom: var(--space-3);">Hematology &#8250; Multiple Myeloma</p>
          <h1 data-animate="slide-up" data-animate-delay="100" class="arca-display-lg arca-text-white" style="margin-bottom: var(--space-5);">
            AI-Driven Benefit-Risk Analysis for Multiple Myeloma
          </h1>
          <p data-animate="slide-up" data-animate-delay="200" class="arca-body-lg" style="color: rgba(255,255,255,0.85); max-width: 680px; margin-bottom: var(--space-7);">
            Multiple myeloma BRA spans CAR-T cell therapies, bispecific antibodies, immunomodulatory agents (IMiDs), and proteasome inhibitors across increasingly complex treatment sequences. ArcaScience delivers CRS and ICANS grading models, secondary malignancy surveillance, and cardiac toxicity monitoring for carfilzomib across all treatment lines.
          </p>
          <div data-animate="slide-up" data-animate-delay="300" style="display: flex; gap: 16px; flex-wrap: wrap;">
            <a href="/platform-overview" class="arca-btn-primary-inverted">See Platform</a>
            <a href="/contact?disease=multiple-myeloma" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">Request Demo</a>
          </div>
        </div>
      </div>
    </section>

    <!-- KEY STATISTICS -->
    <section class="arca-credibility-bar" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="180000" data-countup-suffix="+">180,000+</span>
            <p class="arca-caption">New cases per year globally</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="2100" data-countup-suffix="+">2,100+</span>
            <p class="arca-caption">MM clinical trials analyzed</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="28" data-countup-prefix="$" data-countup-suffix="B">$28B</span>
            <p class="arca-caption">Global MM therapeutics market</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="25" data-countup-suffix="+">25+</span>
            <p class="arca-caption">Approved MM agents tracked</p>
          </div>
        </div>
      </div>
    </section>

    <!-- DISEASE OVERVIEW -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Disease Overview</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">Why Multiple Myeloma Demands Specialized BRA</h2>
          <p class="arca-body-lg arca-text-grey-600">
            Multiple myeloma treatment has been transformed by novel immunotherapies including CAR-T cells and bispecific antibodies, each introducing unprecedented safety profiles such as cytokine release syndrome, immune effector cell-associated neurotoxicity, and deep immunosuppression. With patients receiving 5+ lines of therapy over their disease course, cumulative toxicity modeling and treatment sequencing BRA are essential.
          </p>
        </div>

        <div data-animate-stagger style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">CRS &amp; ICANS from Cell Therapies</h3>
            <p class="arca-body-sm arca-text-grey-600">
              CAR-T therapies (idecabtagene vicleucel, ciltacabtagene autoleucel) and bispecific antibodies (teclistamab, elranatamab, talquetamab) trigger cytokine release syndrome in 70&#8211;95% of patients and ICANS in 15&#8211;25%. While most CRS events are grade 1&#8211;2, grade 3+ CRS and ICANS carry significant morbidity including ICU admission, intubation, and rare fatalities. BRA must model onset kinetics, severity predictors, and the impact of step-up dosing mitigation strategies on both safety and efficacy.
            </p>
          </div>
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Secondary Malignancies &amp; Infections</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Emerging post-marketing data from BCMA-directed CAR-T therapies has raised concern about T-cell malignancies occurring months to years after treatment. Additionally, prolonged B-cell aplasia from both CAR-T and bispecific antibodies creates deep immunosuppression with increased risk of severe infections including COVID-19, invasive fungal disease, and CMV reactivation. IMiD-based maintenance with lenalidomide has established secondary primary malignancy (SPM) signals requiring long-term monitoring.
            </p>
          </div>
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Cardiac Toxicity &amp; IMiD Teratogenicity</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Carfilzomib carries significant cardiovascular toxicity including heart failure, cardiac arrest, and myocardial ischemia, with incidence increasing in patients with pre-existing cardiac risk factors or prior anthracycline exposure. The IMiD class (lenalidomide, pomalidomide) retains the absolute teratogenicity contraindication from thalidomide, requiring REMS programs and mandatory pregnancy prevention, while also carrying venous thromboembolism risk requiring anticoagulation prophylaxis.
            </p>
          </div>
        </div>
      </div>
    </section>

    <!-- ARCASCIENCE APPROACH -->
    <div class="arca-section-divider" aria-hidden="true"></div>

    <section class="arca-bg-grey-50 arca-bg-dots" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Platform Capabilities</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-4);">How ArcaScience Addresses Multiple Myeloma BRA</h2>
          <p class="arca-body-lg arca-text-grey-600" style="max-width: 680px; margin: 0 auto;">
            Our platform is configured with myeloma-specific CRS and ICANS grading models, cell therapy post-marketing surveillance tools, and regulatory templates aligned with ODAC oncology advisory committee and REMS requirements across FDA, EMA, and PMDA.
          </p>
        </div>

        <div data-animate-stagger style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">
          <div class="arca-card arca-card-colored-top is-data" data-animate="slide-up">
            <span class="arca-module-tag is-data">Data Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">Myeloma Data Coverage</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              2,100+ MM clinical trials including KarMMa, CARTITUDE, MajesTEC, MagnetisMM, POLLUX, CASTOR, ASPIRE, and ENDURANCE datasets. CRS and ICANS event data with onset kinetics and severity grading, secondary malignancy tracking, carfilzomib cardiac event profiling, and IMiD teratogenicity and VTE data across all treatment lines from frontline through 5th+ line therapy.
            </p>
            <a href="/platform-data-intelligence" class="arca-btn-tertiary">Explore Data Engine <span class="arca-arrow">&rarr;</span></a>
          </div>

          <div class="arca-card arca-card-colored-top is-analytics" data-animate="slide-up">
            <span class="arca-module-tag is-analytics">Decision Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">Cell Therapy Safety Models</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              AI models for CRS severity prediction based on tumor burden, cytokine biomarkers, and bridging therapy type. ICANS onset prediction and neurotoxicity grading models. Bispecific antibody step-up dosing safety optimization. Comparative BRA across CAR-T and bispecific platforms for relapsed/refractory MM. BRAT framework application with myeloma-specific regulatory precedent from ODAC deliberations and REMS design.
            </p>
            <a href="/platform-ai-models" class="arca-btn-tertiary">Explore AI Models <span class="arca-arrow">&rarr;</span></a>
          </div>

          <div class="arca-card arca-card-colored-top is-output" data-animate="slide-up">
            <span class="arca-module-tag is-output">Automated Outputs</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">Hematology Regulatory Outputs</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              PSURs with CRS/ICANS deep-dives by severity grade and intervention type, REMS-aligned cell therapy monitoring protocols, CTD 2.5 with ORR, PFS, MRD negativity, and OS endpoint summaries, secondary malignancy surveillance reports, and HEOR reports supporting reimbursement submissions for high-cost cell therapy and bispecific products.
            </p>
            <a href="/platform-outputs" class="arca-btn-tertiary">Explore Outputs <span class="arca-arrow">&rarr;</span></a>
          </div>
        </div>
      </div>
    </section>

    <!-- KEY METRICS -->
    <section class="arca-bg-blue-50 arca-bg-mesh" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Multiple Myeloma Intelligence</p>
          <h2 class="arca-display-sm">Platform Performance in Multiple Myeloma</h2>
        </div>
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">
          <div>
            <span class="arca-stat-lg" style="color: var(--green-600);" data-countup="10500000000" data-countup-suffix="+">10,500,000,000+</span>
            <p class="arca-caption arca-text-grey-600">MM adverse event data points</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--green-600);" data-countup="58" data-countup-suffix="%">58%</span>
            <p class="arca-caption arca-text-grey-600">Faster CRS signal characterization</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--green-600);" data-countup="6">6</span>
            <p class="arca-caption arca-text-grey-600">Drug classes modeled for sequencing</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--green-600);" data-countup="12">12</span>
            <p class="arca-caption arca-text-grey-600">Myeloma regulatory submissions supported</p>
          </div>
        </div>
      </div>
    </section>

    <!-- CASE EVIDENCE -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 64px; align-items: center;">
          <div>
            <p class="arca-section-label">Case Evidence &#8212; Multiple Myeloma</p>
            <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">CAR-T Post-Marketing Safety Surveillance Program</h2>
            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--green-600);">Challenge</h3>
              <p class="arca-body-sm arca-text-grey-600">A cell therapy manufacturer required comprehensive post-marketing safety surveillance for their BCMA-directed CAR-T product following accelerated approval. The FDA mandated ongoing secondary malignancy monitoring, real-world CRS and ICANS tracking, and long-term infection surveillance in the broader commercial population, many of whom had more comorbidities and prior treatment lines than clinical trial patients.</p>
            </div>
            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--green-600);">Result</h3>
              <p class="arca-body-sm arca-text-grey-600">ArcaScience deployed cell therapy-specific safety surveillance models that tracked CRS and ICANS severity in real-world patients, monitored secondary malignancy signals with latency-adjusted analysis, and provided continuous benefit-risk updates comparing commercial outcomes against clinical trial benchmarks. The platform identified that real-world CRS rates were 15% lower than pivotal trial data due to improved institutional management protocols, supporting a positive PSUR narrative.</p>
            </div>
            <div style="display: grid; grid-template-columns: repeat(2, 1fr); gap: 24px; margin-bottom: var(--space-6);">
              <div>
                <span class="arca-stat-sm" style="color: var(--green-600);" data-countup="15" data-countup-suffix="%">15%</span>
                <p class="arca-caption arca-text-grey-600">Lower real-world CRS vs. trial rates</p>
              </div>
              <div>
                <span class="arca-stat-sm" style="color: var(--green-600);" data-countup="4.5" data-countup-suffix="x">4.5x</span>
                <p class="arca-caption arca-text-grey-600">Faster secondary malignancy signal detection</p>
              </div>
            </div>
            <a href="/evidence-case-studies-hub" class="arca-btn-tertiary">View All Case Studies <span class="arca-arrow">&rarr;</span></a>
          </div>

          <div class="arca-testimonial" style="text-align: left;">
            <div class="arca-testimonial-quote" style="padding-left: 24px; border-left: 3px solid var(--green-400);">
              ArcaScience&#8217;s CAR-T surveillance platform was instrumental in meeting our FDA post-marketing commitments. The ability to track CRS, ICANS, and secondary malignancies in real time across our commercial patient population&#8212;and compare them against our clinical trial benchmarks&#8212;gave us the evidence base to support continued market access and guide our label update strategy.
            </div>
            <div class="arca-testimonial-attribution" style="margin-top: var(--space-5);">
              <p class="arca-body-md" style="font-weight: 600;">Senior Director, Cell Therapy Pharmacovigilance</p>
              <p class="arca-body-sm arca-text-grey-600">Cell Therapy Manufacturer</p>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- FAQ ACCORDION -->
    <div class="arca-section-divider" aria-hidden="true"></div>

    <section class="arca-bg-teal-100 arca-bg-rings" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Frequently Asked Questions</p>
          <h2 class="arca-display-sm">Multiple Myeloma Benefit-Risk Analysis</h2>
        </div>
        <div style="max-width: 820px; margin: 0 auto;">
          <div data-accordion="group">
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does ArcaScience model CRS severity grading for benefit-risk assessment?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">Our platform uses the ASTCT (Lee) consensus grading criteria and integrates CRS severity with onset kinetics, duration, intervention requirements (tocilizumab, corticosteroids, vasopressors), and clinical outcomes. The AI models predict CRS severity based on pre-treatment factors including tumor burden (measured by serum BCMA levels, M-protein, and bone marrow plasmacytosis), prior treatment lines, bridging therapy type, and baseline inflammatory markers. For bispecific antibodies, we model the impact of step-up dosing schedules on CRS mitigation and how dose modifications affect both safety and depth of response.</p></div>
              </div>
            </div>
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Can the platform compare safety profiles between CAR-T and bispecific antibodies?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">Yes. ArcaScience provides comparative BRA across CAR-T (ide-cel, cilta-cel) and bispecific antibodies (teclistamab, elranatamab, talquetamab) using cross-trial adjusted analyses. We compare CRS incidence and severity, ICANS rates, infection profiles (including depth and duration of B-cell aplasia), manufacturing and logistical considerations, and efficacy endpoints (ORR, CR rate, MRD negativity, PFS). The platform also models the distinct temporal safety profiles&#8212;CAR-T with frontloaded acute toxicity versus bispecifics with ongoing chronic immune suppression from continuous dosing&#8212;to support treatment selection decisions in relapsed/refractory patients.</p></div>
              </div>
            </div>
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does ArcaScience monitor long-term secondary malignancy risk?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">Our platform tracks secondary primary malignancies (SPMs) across all myeloma treatment modalities using latency-adjusted statistical models that account for the delayed onset nature of these events. For CAR-T therapies, we specifically monitor for T-cell lymphomas and myelodysplastic syndrome using both clinical trial long-term follow-up data and real-world registry information. For lenalidomide maintenance, we track the established SPM signal (MDS/AML, solid tumors) with cumulative exposure modeling. The platform provides incidence rate comparisons against expected background cancer rates and flags emerging signals that exceed statistical thresholds.</p></div>
              </div>
            </div>
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Does the platform handle renal impairment dose adjustments in BRA?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">Renal impairment is a hallmark of multiple myeloma and directly impacts drug selection and dosing. Our platform models lenalidomide dose adjustments by CrCl category (including dialysis-dependent patients), carfilzomib infusion rate modifications, and the preferential safety of agents like pomalidomide and daratumumab in renally impaired populations. BRA models incorporate renal function trajectory over treatment duration, accounting for myeloma-related renal recovery with effective therapy and the nephrotoxicity risk of individual agents. This enables renally-adjusted benefit-risk assessments that reflect the real-world myeloma population where 30&#8211;50% of patients have significant renal impairment at diagnosis.</p></div>
              </div>
            </div>
            <div data-accordion-item>
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does minimal residual disease (MRD) status impact BRA modeling?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">MRD negativity (at 10&#8315;&#8309; or 10&#8315;&#8310; sensitivity) is emerging as a key efficacy endpoint in myeloma that directly influences benefit-risk assessment. Our platform models the relationship between depth of response (MRD status) and long-term outcomes (PFS, OS), enabling BRA frameworks that weigh treatment toxicity against the probability of achieving sustained MRD negativity. For frontline transplant-eligible patients, this informs decisions about treatment intensification versus de-escalation. The platform also supports emerging MRD-guided treatment duration strategies where therapy cessation in MRD-negative patients could reduce cumulative toxicity while maintaining efficacy.</p></div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- CTA -->
    <section class="arca-cta-section" data-animate style="position: relative; overflow: hidden;">
      <div style="position: absolute; top: -60px; left: -60px; width: 300px; height: 300px; background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%); border-radius: 50%; filter: blur(40px); pointer-events: none; animation: as-float 7s ease-in-out infinite; z-index: 0;"></div>
      <div style="position: absolute; bottom: -40px; right: -40px; width: 250px; height: 250px; background: radial-gradient(circle, rgba(255,255,255,0.06) 0%, transparent 70%); border-radius: 50%; filter: blur(40px); pointer-events: none; animation: as-float 9s ease-in-out infinite reverse; z-index: 0;"></div>
      <div style="position: relative; z-index: 1; max-width: 680px; margin: 0 auto; padding: 0 24px;">
        <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">See ArcaScience Applied to Multiple Myeloma</h2>
        <p class="arca-body-lg" style="margin-bottom: var(--space-7);">Request a demonstration of ArcaScience&#8217;s platform configured for multiple myeloma benefit-risk analysis. Our hematology scientists will walk through CRS and ICANS grading models, cell therapy surveillance tools, and regulatory output examples tailored to myeloma submissions.</p>
        <div style="display: flex; gap: 16px; justify-content: center; flex-wrap: wrap;">
          <a href="/contact?disease=multiple-myeloma" class="arca-btn-primary-inverted">Request Myeloma Briefing</a>
          <a href="/platform-overview" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">Explore the Platform <span class="arca-arrow">&rarr;</span></a>
        </div>
      </div>
    </section>

  </main>

    <!-- RELATED DISEASES -->
    <section class="arca-bg-grey-50" style="padding: var(--space-7) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-6);">
          <p class="arca-section-label">Explore More</p>
          <h2 class="arca-heading-2" style="margin-bottom: var(--space-3);">
            Related Hematology Disease Pages
          </h2>
        </div>
        <div style="display: flex; flex-wrap: wrap; gap: 12px; justify-content: center;" data-animate-stagger>
          <a href="/ta-hematology" class="arca-card" style="text-decoration: none; color: inherit; padding: var(--space-3) var(--space-5); text-align: center;" data-animate="slide-up">
            <span class="arca-heading-4" style="display: block; margin-bottom: 4px;">&larr; All Hematology</span>
            <span class="arca-body-sm arca-text-grey-500">Back to overview</span>
          </a>
          <a href="/disease-cll" class="arca-card" style="text-decoration: none; color: inherit; padding: var(--space-3) var(--space-5); text-align: center;" data-animate="slide-up">
            <span class="arca-heading-4" style="display: block; margin-bottom: 4px;">CLL</span>
            <span class="arca-body-sm arca-text-grey-500">BTK inhibitor and venetoclax benefit-risk profiling for CLL and small lymphocytic lymphoma.</span>
            <span class="arca-body-sm arca-text-grey-500" style="display: block; margin-top: 4px;">View BRA &rarr;</span>
          </a>
          <a href="/disease-sickle-cell" class="arca-card" style="text-decoration: none; color: inherit; padding: var(--space-3) var(--space-5); text-align: center;" data-animate="slide-up">
            <span class="arca-heading-4" style="display: block; margin-bottom: 4px;">Sickle Cell Disease</span>
            <span class="arca-body-sm arca-text-grey-500">Gene therapy and disease-modifying therapy safety surveillance for sickle cell disease.</span>
            <span class="arca-body-sm arca-text-grey-500" style="display: block; margin-top: 4px;">View BRA &rarr;</span>
          </a>
        </div>
      </div>
    </section>

  <!-- FOOTER -->
  <footer class="arca-bg-blue-900" style="padding: var(--space-9) 0 var(--space-7);">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
      <div style="display: grid; grid-template-columns: 2fr 1fr 1fr 1fr 1fr; gap: 48px;">
        <div>
          <img src="/images/arcascience-logo-white.svg" alt="ArcaScience" height="28" style="margin-bottom: var(--space-5);">
          <p class="arca-body-sm" style="color: rgba(255,255,255,0.65); max-width: 280px;">AI-driven benefit-risk analysis for pharmaceutical development. Founded 2018.</p>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Platform</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/platform-overview" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Overview</a>
            <a href="/platform-data-intelligence" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Data Intelligence</a>
            <a href="/platform-ai-models" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Decision Intelligence</a>
            <a href="/platform-outputs" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Regulatory Outputs</a>
            <a href="/security-compliance" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Security & Compliance</a>
          </nav>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Solutions</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Therapeutic Areas</a>
            <a href="/ta-oncology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Oncology</a>
            <a href="/ta-neurology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Neurology</a>
            <a href="/ta-immunology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Immunology</a>
            <a href="/ta-cardiology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Cardiology</a>
            <a href="/ta-respiratory" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Respiratory</a>
            <a href="/ta-rare-diseases" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Rare Diseases</a>
            <a href="/ta-hematology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Hematology</a>
            <a href="/ta-dermatology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Dermatology</a>
            <a href="/solution-early-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Early Development</a>
            <a href="/solution-late-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Late Development</a>
          </nav>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Company</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">About</a>
            <a href="/leadership" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Team</a>
            <a href="/careers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Careers</a>
            <a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">News</a>
            <a href="/contact" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Contact</a>
          </nav>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Resources</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/evidence-case-studies-hub" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Case Studies</a>
            <a href="/resources-whitepapers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Whitepapers</a>
            <a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Blog</a>
            <a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Documentation</a>
          </nav>
        </div>
      </div>
      <div style="margin-top: var(--space-8); padding-top: var(--space-5); border-top: 1px solid rgba(255,255,255,0.1); display: flex; justify-content: space-between; align-items: center;">
        <p class="arca-caption" style="color: rgba(255,255,255,0.45);">&copy; 2026 ArcaScience. All rights reserved.</p>
        <div style="display: flex; gap: 24px;">
          <a href="/legal-privacy" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Privacy</a>
          <a href="/legal-terms" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Terms</a>
          <a href="/legal-cookies" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Cookies</a>
          <a href="/legal-accessibility" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Accessibility</a>
        </div>
      </div>
    </div>
  </footer>

  <button data-back-to-top aria-label="Back to top">
    <svg width="16" height="16" viewBox="0 0 16 16" fill="none"><path d="M8 12V4M4 7l4-4 4 4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round"/></svg>
  </button>

  <script src="/dist/arcascience-global.min.js" defer></script>
  <script src="/dist/arcascience-countup.min.js" defer></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      if (window.ArcaScience) ArcaScience.init();
      if (window.ArcaScienceCountUp) ArcaScienceCountUp.init({ selector: '[data-countup]' });
    });
  </script>
</body>
</html>
